531 related articles for article (PubMed ID: 22652556)
1. On-line haemodiafiltration improves response to calcifediol treatment.
Pérez-García R; Albalate M; de Sequera P; Alcázar R; Puerta M; Ortega M; Corchete E
Nefrologia; 2012 Jul; 32(4):459-66. PubMed ID: 22652556
[TBL] [Abstract][Full Text] [Related]
2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of 25(OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis.
Del Valle E; Negri AL; Aguirre C; Fradinger E; Zanchetta JR
Hemodial Int; 2007 Jul; 11(3):315-21. PubMed ID: 17576296
[TBL] [Abstract][Full Text] [Related]
6. Risk in dosing regimens for 25-OH vitamin D supplementation in chronic haemodialysis patients.
Albalate M; de la Piedra C; Ortiz A; Hernández Pérez J; Rubert M; Pérez Garcia R; Zazo P; Nieto L; de Sequera P; Egido J
Nephron Clin Pract; 2012; 121(3-4):c112-9. PubMed ID: 23221739
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
Blair D; Byham-Gray L; Lewis E; McCaffrey S
J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
[TBL] [Abstract][Full Text] [Related]
8. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients.
Fiedler R; Deuber HJ; Langer T; Osten B; Mohan S; Jehle PM
Nephron Clin Pract; 2004; 96(1):c3-9. PubMed ID: 14752247
[TBL] [Abstract][Full Text] [Related]
9. Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency.
Trakarnvanich T; Chalapipat O; Disthabanchong S; Kurathong S; Praditpornsilpa K; Stitchantrakul W; Chailurkit LO
J Med Assoc Thai; 2010 Aug; 93(8):885-91. PubMed ID: 20718162
[TBL] [Abstract][Full Text] [Related]
10. Correlation of serum magnesium with serum parathormone levels in patients on regular hemodialysis.
Baradaran A; Nasri H
Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):344-50. PubMed ID: 16970254
[TBL] [Abstract][Full Text] [Related]
11. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D status of chronic kidney disease patients living in a sunny country.
Cuppari L; Carvalho AB; Draibe SA
J Ren Nutr; 2008 Sep; 18(5):408-14. PubMed ID: 18721735
[TBL] [Abstract][Full Text] [Related]
13. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
[TBL] [Abstract][Full Text] [Related]
14. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
15. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068
[TBL] [Abstract][Full Text] [Related]
16. High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients.
Tokmak F; Quack I; Schieren G; Sellin L; Rattensperger D; Holland-Letz T; Weiner SM; Rump LC
Nephrol Dial Transplant; 2008 Dec; 23(12):4016-20. PubMed ID: 18593741
[TBL] [Abstract][Full Text] [Related]
17. [Review of the concept of vitamin D "sufficiency and insufficiency"].
Gómez Alonso C; Naves Díaz M; Rodríguez García M; Fernández Martín JL; Cannata Andía JB
Nefrologia; 2003; 23 Suppl 2():73-7. PubMed ID: 12778859
[TBL] [Abstract][Full Text] [Related]
18. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients.
Matias PJ; Ferreira C; Jorge C; Borges M; Aires I; Amaral T; Gil C; Cortez J; Ferreira A
Nephrol Dial Transplant; 2009 Feb; 24(2):611-8. PubMed ID: 18775809
[TBL] [Abstract][Full Text] [Related]
19. [Urinary excretion of free and total deoxypyridinoline during secondary hyperparathyroidism in the elderly. Comparison of chromatographic (HPLC) and immunoenzymatic (Pyrilinks-D) methods].
Meddah B; Brazier M; Kamel S; Maamer M; Samson L; Desmet G; Sebert JL
Ann Biol Clin (Paris); 1996; 54(10-11):353-8. PubMed ID: 9092303
[TBL] [Abstract][Full Text] [Related]
20. Assessment of immune status in relation to vitamin D levels in children on regular hemodialysis.
Youssef DM; Elshal AS; Abo Elazem AA
Saudi J Kidney Dis Transpl; 2012 Mar; 23(2):267-73. PubMed ID: 22382217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
